Dendritic cells as therapeutic vaccines against cancer

Nat Rev Immunol. 2005 Apr;5(4):296-306. doi: 10.1038/nri1592.


Mouse studies have shown that the immune system can reject tumours, and the identification of tumour antigens that can be recognized by human T cells has facilitated the development of immunotherapy protocols. Vaccines against cancer aim to induce tumour-specific effector T cells that can reduce the tumour mass, as well as tumour-specific memory T cells that can control tumour relapse. Owing to their capacity to regulate T-cell immunity, dendritic cells are increasingly used as adjuvants for vaccination, and the immunogenicity of antigens delivered by dendritic cells has now been shown in patients with cancer. A better understanding of how dendritic cells regulate immune responses will allow us to better exploit these cells to induce effective antitumour immunity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation*
  • Humans
  • Immune Tolerance / immunology
  • Neoplasms / immunology
  • Neoplasms / therapy*


  • Cancer Vaccines